Home Cart Sign in  
Chemical Structure| 1505515-69-4 Chemical Structure| 1505515-69-4

Structure of Taletrectinib
CAS No.: 1505515-69-4

Chemical Structure| 1505515-69-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Taletrectinib is a new-generation selective ROS1/Trk Receptor inhibitor with IC50 values of 0.207nM, 0.622nM, 2.28nM and 0.98nM for ROS1, Trk Receptor A, B and C, respectively. It induces dramatic growth inhibition of both wild type and G2032R mutant ROS1-rearranged cancers or NTRK-rearranged cancers in vitro and in vivo.

Synonyms: DS-6051b; AB-106; IBI-344

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Taletrectinib

CAS No. :1505515-69-4
Formula : C29H34FN5O5
M.W : 551.61
SMILES Code : O=C(O)CCCCC(O)=O.C[C@@H](NC1=NN2C(C=C1)=NC=C2C3=CC=C(OC[C@H](N)C)C=C3)C4=CC=CC(F)=C4
Synonyms :
DS-6051b; AB-106; IBI-344
MDL No. :MFCD32708526
InChI Key :DORJQZDOULKINH-QNBGGDODSA-N
Pubchem ID :72694302

Safety of Taletrectinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Taletrectinib

RTK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04395677 Non Small Cell Lung Cancer PHASE2 ACTIVE_NOT_RECRUITING 2025-12-31 Shanghai Pulmonary Hospital, S... More >>hanghai, Shanghai, 200000, China Less <<
NCT06214793 Breast Cancer|Metastatic Breas... More >>t Cancer Less << PHASE2 SUSPENDED 2030-01-01 Marone Cancer Center Cleveland... More >> Clinic Florida, Weston, Florida, 33331, United States|Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, 44195, United States Less <<
NCT04919811 Non Small Cell Lung Cancer PHASE2 RECRUITING 2025-06-27 Beverly Hills Cancer Center, B... More >>everly Hills, California, 90211, United States|Moores Cancer Center at UC San Diego, La Jolla, California, 92037, United States|Keck Medicine of University of Southern California, Los Angeles, California, 90089, United States|UCI Medical Center, Orange, California, 92868, United States|PMK Medical Group Inc, Oxnard, California, 93030, United States|American Institute of Research, Whittier, California, 90601, United States|SCRI - Florida Cancer Specialists South, Fort Meyers, Florida, 33901, United States|Memorial Healthcare System, Hollywood, Florida, 33021, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 92868, United States|SCRI - Hematology Oncology Clinic, Baton Rouge, Louisiana, 70809, United States|Mayo Clinic, Rochester, Minnesota, 55902, United States|Center for Cancer Research, Brick, New Jersey, 08724, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|SCRI - Tennessee Oncology, Nashville, Tennessee, 37203, United States|Renovatio Clinical, Dallas, Texas, 75001, United States|Texas Oncology, P.A., Dallas, Texas, 75246, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Renovatio Clinical - The Woodlands, Houston, Texas, 77056, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre Research Institute, Montréal, Quebec, Canada|Hunan Cancer Hospital, Changsha, China|West China Hospital, Chengdu, China|Shandong Cancer Hospital, Jinan, China|Wuhan Union Hospital, Wuhan, China|Henan Cancer Hospital, Zhengzhou, China|CHU Lyon - H?pital Cardio-Vasculaire et Pneumologique Louis Pradel, Bron, France|CHU de Grenoble - H?pital Albert Michallon, Grenoble, France|Centre Léon Bérard, Lyon, France|H?pital Nord - CHU Marseille, Marseille, France|ICO - Site René Gauducheau, Nantes, France|H?pital Européen Georges Pompidou, Paris, France|CHU Poitiers - Hopital la Miletrie, Poitiers, France|Godinot Cancer Institute, Reims, France|CHU Rennes - Hopital Pontchaillou, Rennes, France|Institut Gustave Roussy, Villejuif, France|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico, Bari, Italy|Humanitas Istituto Clinico Catanese, Misterbinanoco, Catania, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IEO Istituto Europeo di Oncologia, Milano, Italy|Ospedale San Raffaele, Milano, Italy|AOU Cagliari- P.O. Policlinico Universitario Duilio Casula, Monserrato, Italy|Azienda Ospedaliera Universitaria- Università degli Studi della Campania, Napoli, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|National Cancer Center Hospital East, Kashiwa, Japan|Sendai Kousei Hospital, Miyagi, Japan|Aichi Cancer Center Hospital, Nagoya, Japan|Kindai University Hospital, Osaka, Japan|Shizuoka Cancer Center, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Pusan National University Hospital, Busan, 612-022, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsang, 999007, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, 540-742, Korea, Republic of|Asan Medical Center, Seoul, 05742, Korea, Republic of|Korea University Guro Hospital, Seoul, 130-875, Korea, Republic of|Med-Polonia Sp. z o.o., Poznań, Poland|MICS Centrum Medyczne Toruńa, Toruń, Poland|Instytut Centrum Zdrowia Matki Polki, ?ód?, Poland|Clinica Mi Tres Torres, Barcelona, Spain|Hospital General de Catalunya, Barcelona, Spain|Hospital Quironsalud Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Quironsalud Madrid, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Instituto Valenciano de Oncologia IVO, Valencia, Spain Less <<
NCT02675491 Advanced Solid Malignant Tumor... More >>s Less << PHASE1 COMPLETED 2021-12-28 National Hospital Organization... More >> Kyushu Cancer Center, Fukuoka, Japan|Kinki University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan Less <<
NCT04617054 Solid Tumor PHASE2 RECRUITING 2026-12-31 Chinese PLA General Hospital, ... More >>Beijing, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.81mL

0.36mL

0.18mL

9.06mL

1.81mL

0.91mL

18.13mL

3.63mL

1.81mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories